Novartis Ag (NVS) Net Margin (2009 - 2026)
Novartis Ag (NVS) posted Net Margin of 22.65% for Q2 2026, down 92.42% sequentially from 298.74% in Q2 2025, and down 27609.0% YoY from N/an in Q2 2025.
Novartis Ag (NVS) Net Margin (2009 - 2026) Analysis & Trends
Novartis Ag has reported Net Margin for 18 years, with the latest figure at 22.65% in Q2 2026.
- Quarterly Net Margin fell 27609.0% year-over-year to 22.65% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 21.03% (down 14755.0% YoY) and the FY2025 annual result came in at 25.64%, down 6189.0% from the prior year.
- Net Margin retreated to 22.65% in Q2 2026 per NVS's latest filing, from 298.74% in the prior quarter.
- Over five years, Net Margin peaked at 13230105.84% in Q1 2022 and troughed at 22.65% in Q2 2026.
- A 5-year average of 1102725.43% and a median of 229.83% in 2023 frame the typical range for Net Margin.
- The sharpest annual moves came in 2022 and 2023: Net Margin soared 824743359 bps in 2022, then sank 1323006139 bps in 2023.
- Over 5 years, Net Margin stood at 234.44% in 2022, then fell by 10 bps to 209.88% in 2023, then declined by 14 bps to 180.95% in 2024, then surged by 65 bps to 298.74% in 2025, then slumped by 92 bps to 22.65% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 22.65%, 298.74%, and 180.95% for Q2 2026, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 21.86% |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 21.28% |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -8.05% |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 22.65% |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 16.30% |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 23.62% |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -134.51% |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -1.58% |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 5.17% |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 2.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.65% |
| Jun 30, 2025 | 298.74% |
| Dec 31, 2024 | 180.95% |
| Jun 30, 2024 | 333.54% |
| Dec 31, 2023 | 209.88% |
| Sep 30, 2023 | 225.23% |
| Jun 30, 2023 | 453.33% |
| Mar 31, 2023 | 44.44% |
| Dec 31, 2022 | 234.44% |
| Sep 30, 2022 | 103.81% |
| Jun 30, 2022 | 492.33% |
| Mar 31, 2022 | 13,230,105.84% |
| Dec 31, 2021 | 266.70% |
| Sep 30, 2021 | -4,371.88% |
| Jun 30, 2021 | 417.12% |
| Mar 31, 2021 | 4,982,672.24% |
| Dec 31, 2020 | 239.52% |
| Sep 30, 2020 | 7,563,609.66% |
| Jun 30, 2020 | 474.24% |
| Mar 31, 2020 | 81.17% |